Ozempic Butt: Why It Happens and How to Avoid and Fix It

“Ozempic butt” is the social-media name for a deflated, flattened, or sagging backside after fast weight loss on a GLP-1 medication. It is not a toxic effect of semaglutide or tirzepatide on the buttocks — it is the cosmetic consequence of three things happening together: the subcutaneous fat that gave the buttocks their roundness shrinks, a meaningful share of the weight lost is lean (muscle) mass — roughly a quarter of total weight loss in the SURMOUNT-1 DXA substudy (Look 2025^[1]) — so the gluteal muscles get smaller, and the previously stretched skin over a now-smaller area drapes and looks loose. It belongs to the same family as “Ozempic face”: rapid-weight-loss body-composition change made visible. The good news is that the part you most control — the muscle — responds to the same two interventions with the strongest evidence: resistance training and adequate protein. This article covers what it is, why it happens, how much of GLP-1 weight loss is lean mass, how to avoid it, and how to fix it.

What "Ozempic butt" actually is

“Ozempic butt” is a colloquial, not a medical, term. It describes a buttocks that looks smaller, flatter, softer, or saggier after substantial weight loss on a GLP-1 receptor agonist (semaglutide — Ozempic, Wegovy; or tirzepatide — Mounjaro, Zepbound). People notice it as loss of projection and fullness, a “deflated” quality, crepey or loose skin over the upper thigh and lower glute, and sometimes a more pronounced fold where the buttock meets the thigh.

The crucial point is that this is not a drug toxicity directed at the gluteal region. No GLP-1 has any known pharmacological action on buttock tissue specifically. It is the same phenomenon that has been described for decades after bariatric surgery, very-low-calorie diets, and any other route to fast, large weight loss. GLP-1 medications draw attention because they reliably produce large, rapid weight loss — tirzepatide averaged about −21% body weight in the SURMOUNT-1 pivotal trial (Jastreboff 2022^[2]) and semaglutide about −15% in STEP-1 (Wilding 2021^[3]) — so the body-composition signal is simply more visible, faster.

Why it happens — fat loss, lean-mass loss, and skin laxity

1. Subcutaneous gluteal fat shrinks

The roundness and projection of the buttocks come largely from the gluteofemoral subcutaneous fat depot. This depot is metabolically distinct from belly fat — it is generally protective and slower to mobilize (Manolopoulos 2010^[4]) — but during a sustained, large caloric deficit it does shrink along with the rest of the body's fat stores. Because the buttock is a high-fat, low-other-tissue area, losing that subcutaneous fat has an outsized visual effect: there is less underneath to fill out the skin. This is the single biggest driver of the deflated look, and to a large degree it is the intended result of the weight loss — the same fat loss that improves metabolic health.

2. A share of the weight lost is muscle

Every weight-loss method — diet, surgery, or GLP-1 — takes some lean (muscle) tissue along with the fat. In the SURMOUNT-1 DXA body-composition substudy (Look 2025^[1]), tirzepatide produced roughly −33.9% fat mass and −10.9% lean mass at week 72, so about 25% of the total weight lost was lean tissue — and the placebo arm showed the same fat-to-lean split, confirming the ratio reflects rate-of-weight-loss physiology, not a drug-specific effect. When the gluteus maximus and the surrounding muscles lose volume, the buttocks lose their underlying shape and lift. This lean-mass component is what makes “Ozempic butt” different from simply losing fat: without resistance training, the muscle that shapes the buttock shrinks too. Our GLP-1 muscle-loss prevention protocol and tirzepatide lean-mass deep-dive cover the body-composition evidence in full.

3. Skin that was stretched now drapes

Skin that has been stretched over a larger volume for a long time does not always retract fully when the volume underneath disappears, especially with faster loss, larger total loss, older age, sun damage, and genetics. The result is laxity — crepey, loose, or sagging skin over the lower buttock and upper thigh. This is the same mechanism behind loose skin after GLP-1 weight loss elsewhere on the body; see also our guide on how to tighten loose skin after weight loss.

Put the three together — less fat, less muscle, looser skin — and you get the characteristic flattened, softened backside. The fat loss is mostly desired; the muscle loss and skin laxity are the parts worth actively managing.

The body-composition evidence: how much of GLP-1 weight loss is lean mass

The honest, sourced numbers matter here, because the “muscle” part of “Ozempic butt” is the part you can most influence.

• Tirzepatide (SURMOUNT-1 DXA substudy, Look 2025^[1]): at week 72, total body weight −21.3%, fat mass −33.9%, lean mass −10.9% — about 25% of total weight lost was lean tissue. The same 75/25 fat-to-lean split appeared in the placebo arm.
• Semaglutide (STEP-1, Wilding 2021^[3]): −14.9% total body weight at week 68, with a DXA pattern in the same range — fat mass dropped more than lean mass, but lean mass still accounted for a meaningful share of the loss.
• Across all modalities (Cava 2017^[5]): the lean-tissue fraction of weight lost clusters around 20–30% for moderate-rate loss and tilts higher with faster loss — GLP-1 weight loss is not an outlier.
• Rate matters: faster weight loss tends to take a higher proportion of lean tissue, which is why slower titration and protein-plus-training are the levers (Stefanakis 2024^[9]).

The takeaway for the buttocks specifically: roughly a quarter of what you lose is, by default, lean mass — and the gluteal muscles are a large, visible muscle group. Protect that muscle and you protect a large part of the shape.

How to AVOID it — protect muscle while you lose fat

You cannot lose 15–25% of your body weight without some change to the buttocks — the fat that gave it volume is part of what is coming off. But you can substantially change how much of the loss is muscle versus fat, and you can preserve the underlying shape. Three interventions have the strongest evidence.

1. Resistance training, with glute-focused work, 2–3 sessions per week. This is the single highest-evidence intervention. Sardeli 2018^[6] meta-analyzed RCTs of resistance training during caloric restriction and found it essentially abolished the lean-mass loss otherwise seen with diet alone. Murphy and Koehler 2022^[10] showed that even in an energy deficit, resistance training still attenuates lean-mass loss and preserves strength. For the buttocks, prioritize compound lower-body movements that load the glutes — squats, hip hinges (deadlift, Romanian deadlift), and hip thrusts — alongside a full-body program.
2. Protein at 1.2–1.6 g/kg per day (up to ~2.0 g/kg on a GLP-1). Krieger 2006^[7] and Phillips 2016^[8] converge on roughly 1.6 g/kg as the practical target for preserving fat-free mass in a deficit; Longland 2016^[11] randomized men in a steep deficit to 1.2 vs 2.4 g/kg and the high-protein arm actually gained lean mass while losing fat; Wycherley 2012^[12] confirmed higher-protein diets reduce fat-free-mass loss. The challenge on a GLP-1 is hitting the target when appetite is cut — prioritize protein first at each meal.
3. Slower titration / slower rate of loss, where appropriate. Because faster loss takes proportionally more lean tissue, discussing a more gradual dose escalation with your prescriber can reduce the share of weight lost as muscle and give skin more time to adapt (Stefanakis 2024^[9]).

How to FIX it — rebuild, tighten, and the cosmetic options

Rebuild the muscle (the highest-leverage fix)

The most effective and lowest-risk way to restore shape is to rebuild the gluteal muscle with progressive resistance training. Unlike fat loss, muscle can be regained, and the glutes respond strongly to direct loading. A program built around hip thrusts, squats, hip hinges, and lunges — 2–3 sessions per week with progressive overload — rebuilds the underlying volume and lift over weeks to months. Pairing this with adequate protein is what turns training into actual muscle. This is the same protocol used to prevent the change, applied after the fact; it works best once weight has stabilized so you are no longer in a steep deficit.

Skin tightening

Skin laxity is harder to reverse than muscle loss. Mild laxity often improves over months as skin slowly retracts, and is helped by reaching a stable weight, staying hydrated, not smoking, and protecting skin from sun. For more significant laxity, non-surgical energy-based devices (radiofrequency and ultrasound-based skin-tightening) are used cosmetically, and surgical options for the body exist for substantial excess skin — the post-bariatric body-contouring literature (Sadeghi 2022^[13]) describes these procedures, though most published work focuses on the abdomen and arms rather than the buttocks specifically. See our dedicated guide on tightening loose skin after weight loss.

Cosmetic volume restoration (elective)

If muscle rebuilding and skin tightening do not fully restore the desired shape, several elective cosmetic procedures can add volume. These are aesthetic, optional, and carry their own costs and risks — described here neutrally, not recommended:

• Autologous fat transfer (Brazilian butt lift, BBL): liposuctioned fat from elsewhere is injected into the buttocks to restore volume and projection. It is a surgical procedure and, with rapid weight loss, results depend on having enough donor fat and on weight stability afterward.
• Biostimulatory injectables: agents such as poly-L-lactic acid and calcium hydroxylapatite are used off the face to stimulate collagen and add gradual volume to areas including the buttocks. These are non-surgical but require a series of sessions and have temporary results.
• Surgical gluteal augmentation / lift: for combined volume loss and significant skin excess, plastic surgeons offer buttock lift and augmentation procedures, sometimes alongside body-contouring after major weight loss.

For any of these, the practical advice mirrors the “Ozempic face” guidance: time cosmetic intervention after weight has stabilized for a few months, because treating before the target weight is reached produces volume mismatches that need re-treatment as more weight comes off. Bring your starting weight, current weight, and titration plan to the consultation.

Why muscle preservation matters beyond appearance

The gluteal and leg muscles are not only cosmetic — they are central to strength, balance, and metabolic health. Excess lean-mass loss matters most in older adults and in anyone at risk of sarcopenia (age-related muscle loss). The EWGSOP2 (Cruz-Jentoft 2019^[14]) and ESPEN/EASO sarcopenic-obesity (Donini 2022^[15]) consensus statements define when to screen muscle strength and mass formally — relevant for patients age 65 or older or with low baseline strength starting a GLP-1. In other words, the same resistance training and protein that keep the buttocks shapely also protect function and reduce fall and frailty risk. That is the strongest reason to treat the muscle side of “Ozempic butt” seriously rather than purely cosmetically.

When it is a body-image concern, not just a cosmetic one

Rapid changes in body shape can be psychologically complex even when the weight loss is wanted. Some people feel distress about their changed appearance, or notice that reaching a goal weight did not resolve dissatisfaction the way they expected. If preoccupation with the buttocks or body shape becomes distressing, intrusive, or starts driving restrictive behavior, that is worth raising with a clinician — our guide on body image, disclosure, and post-loss grief on a GLP-1 covers this in depth. “Ozempic butt” is a real and common cosmetic effect, and it is also one that is partly addressable through training and, if desired, cosmetic options — framing it accurately helps keep it in proportion.

Bottom line

• “Ozempic butt” is the deflated, flattened, or sagging buttocks seen after rapid GLP-1 weight loss — a body-composition and skin effect, not a drug toxicity to the buttocks.
• It is driven by three things: loss of gluteal subcutaneous fat, loss of gluteal muscle (about 25% of GLP-1 weight loss is lean mass per the SURMOUNT-1 DXA substudy^[1]), and skin laxity over a previously stretched area.
• To avoid it: resistance training with glute-focused work 2–3x/week (Sardeli 2018^[6]), protein 1.2–1.6 g/kg (up to ~2.0 on a GLP-1), and slower titration where appropriate.
• To fix it: rebuild glute muscle with progressive resistance training (the highest-leverage, lowest-risk fix), support skin retraction, and — if desired — consider elective cosmetic options (fat transfer/BBL, biostimulators, surgical lift) once weight is stable.
• Preserving muscle is about more than looks — it protects strength, balance, and metabolic health, especially in older adults at risk of sarcopenia (Cruz-Jentoft 2019^[14]).
• If the change becomes a source of significant distress, treat it as a body-image concern worth discussing with a clinician.

Related research

• Ozempic face — the same subcutaneous-fat-loss mechanism in the face, imaging-quantified.
• Ozempic vulva — body-region fat loss in the external female genitals after GLP-1 weight loss.
• Ozempic penis — the male counterpart, including the buried-penis fat-loss effect.
• Preventing muscle loss on a GLP-1 — the resistance-training and protein protocol that protects the glutes.

Important disclaimer. This article is educational and does not constitute medical, exercise, or cosmetic-procedure advice. Resistance-training programs should be individualized and, for patients with cardiovascular disease, prior injury, or significant deconditioning, supervised by a qualified clinician or certified strength coach. Protein targets assume normal renal function. Cosmetic and surgical procedures are elective and carry their own risks; discuss them with a board-certified provider. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-19.